We have a diverse pipeline of multi-targeted therapies in development for both inflammatory disease and oncology.
Conditional CD28 Costimulator and Dual PD-L1/CTLA-4 Inhibitor
Davoceticept is engineered to provide direct T cell costimulation and dual checkpoint inhibition to enable the immune system to mount a robust anti-tumor response.
We are currently enrolling NEON-1, a Phase 1 dose escalation and expansion study of davoceticept in patients with advanced malignancies (NCT04186637).
NEON-2, a Phase 1 combination study of davoceticept with KEYTRUDA® (pembrolizumab) in patients with advanced malignancies is active, not recruiting (NCT04920383).
Dual B Cell Cytokine Antagonist of BAFF and APRIL
ALPN-303 is a dual B cell cytokine antagonist being developed for multiple autoimmune and/or inflammatory diseases.
We are currently enrolling in a Phase 1 study of ALPN-303 in healthy volunteers (NCT05034484). This study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of ALPN-303. Multiple dose levels will be tested to help assess ALPN-303’s potential for the treatment of inflammatory diseases.
Dual CD28/ICOS Antagonist
Acazicolcept is a first-in-class dual inhibitor of the CD28 and ICOS T cell costimulatory pathways. The molecule is being developed for treatment of severe inflammatory diseases.
We are currently enrolling Synergy, a Phase 2 study of acazicolcept in patients with Systemic Lupus Erythematosus (NCT04835441). This randomized, double-blind, placebo-controlled study was designed to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of acazicolcept.